lonafarnib has been researched along with Amazon Black Fever in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, AU; Lee, C | 1 |
| Keskin, O; Yurdaydin, C | 1 |
| Deterding, K; Wedemeyer, H | 1 |
| Caviglia, GP; Ibadullaeva, N; Ismoilov, U; Joldasova, E; Khikmatullaeva, A; Khodjaeva, M; Musabaev, E; Rizzetto, M; Said, S; Shahnoza, A | 1 |
| Dhillon, S | 1 |
| Elazar, M; Glenn, JS | 1 |
| Bram, Y; Chiriboga, L; Cullen, J; Frankel, AS; Gerges, S; Giersch, K; Heller, B; Hrebikova, G; Huang, T; Johnson, H; Low, BE; Lutgehetmann, M; Nahass, RG; Pais, MA; Ploss, A; Schwartz, RE; Sellau, J; Seneca, K; Sharon, Y; Shirvani-Dastgerdi, E; Toettcher, JE; Wiles, MV; Winer, BY | 1 |
| Yurdaydin, C | 1 |
5 review(s) available for lonafarnib and Amazon Black Fever
| Article | Year |
|---|---|
Hepatitis D Review: Challenges for the Resource-Poor Setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Humans; Interferon-alpha; Lipopeptides; Piperidines; Pyridines; Treatment Outcome; Viral Load; Virus Replication | 2021 |
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Drug-Related Side Effects and Adverse Reactions; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Polymers; Pyridines; Recurrence; Treatment Outcome | 2019 |
Lonafarnib: First Approval.
Topics: Antiviral Agents; Enzyme Inhibitors; Farnesyltranstransferase; Hepatitis D; Humans; Piperidines; Progeria; Pyridines | 2021 |
Emerging concepts for the treatment of hepatitis delta.
Topics: Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis D; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Mice; Piperidines; Pyridines | 2017 |
New treatment options for delta virus: Is a cure in sight?
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Interleukins; Lipopeptides; Nucleic Acids; Piperidines; Polyethylene Glycols; Polymers; Pyridines | 2019 |
3 other study(ies) available for lonafarnib and Amazon Black Fever
| Article | Year |
|---|---|
Emerging drugs for hepatitis D.
Topics: Antiviral Agents; Hepatitis D; Hepatitis D, Chronic; Humans; Nucleic Acids; Polyethylene Glycols; Polymers; Ritonavir; Treatment Outcome | 2023 |
Hepatitis D virus in Uzbekistan.
Topics: Adult; Chronic Disease; Female; Fibrosis; Global Burden of Disease; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Humans; Incidence; Interferon-alpha; Lipopeptides; Liver Diseases; Male; Middle Aged; Piperidines; Prevalence; Pyridines; Risk Factors; Superinfection; Uzbekistan | 2020 |
Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Topics: Adaptive Immunity; Animals; Disease Models, Animal; Drug Therapy, Combination; Genome, Viral; Glycoproteins; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Hepatocytes; Humans; Immunity, Innate; Immunocompetence; Lipopeptides; Mice, Inbred C57BL; Mice, Transgenic; Organic Anion Transporters, Sodium-Dependent; Piperidines; Pyridines; Symporters; Transgenes; Viremia | 2018 |